The cell therapy market size has grown rapidly in recent years. It will grow from $16.87 billion in 2025 to $19.31 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to high cost of autologous therapies, limited donor availability, lack of standardized manufacturing, early-stage clinical trial success, rising incidence of chronic diseases.
The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $32.48 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to advancements in gene editing, automation in cell manufacturing, growing investment in cell therapy startups, increasing demand for regenerative medicine, expanding application across oncology and cvd. Major trends in the forecast period include personalized cell therapy development, allogeneic therapy advancements, improved cell storage & transportation, regulatory & compliance innovations, emerging clinical applications.
The rising prevalence of chronic diseases has supported the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), a chronic disease is a condition lasting one year or more that requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells offer potential benefits for patients with spinal cord injuries, type 1 diabetes, Parkinson’s disease, heart disease, cancer, and osteoarthritis. For example, in July 2024, the CDC reported significant updates on public health initiatives: over 944,800 Americans die annually from heart disease or stroke, representing more than one-third of all deaths; 1.7 million are diagnosed with cancer each year, with over 600,000 fatalities, making it the second leading cause of death; more than 38 million Americans have diabetes, with 98 million adults prediabetic; and obesity affects 20% of children and 42% of adults, increasing the risk of type 2 diabetes, heart disease, and certain cancers. This growing prevalence of chronic diseases has driven demand for cell therapies, contributing to market expansion.
Key players in the cell therapy market are developing next-generation, multi-targeted therapies backed by strong early-stage clinical data to improve treatment outcomes and address unmet needs in complex cancers. For instance, in June 2025, Johnson & Johnson, a US-based pharmaceutical company, reported promising initial results from its Phase 1b study of JNJ-4496, a dual-targeting CAR T-cell therapy designed to bind both CD19 and CD20 in relapsed or refractory large B-cell lymphoma. Early data presented at the 2025 EHA Congress showed 75-80% complete responses at the recommended Phase 2 dose, with no Grade 3-4 cytokine release syndrome. The therapy demonstrated encouraging safety, manageable neurotoxicity, and robust activity even in heavily pretreated patients, highlighting the potential of next-generation dual-targeting CAR T therapies and reinforcing Johnson & Johnson’s commitment to advancing innovative treatments for B-cell malignancies.
In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Sigilon Therapeutics for $34.6 million. This acquisition allows Lilly to strengthen its research and development in encapsulated cell therapies, specifically targeting Type 1 diabetes with its lead candidate, SIG-002, bolstering its position in the diabetes treatment market. Sigilon Therapeutics is a US-based biotechnology company focused on developing innovative cell therapies.
Major companies operating in the cell therapy market are Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics plc, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Athersys Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, Cellular Biomedicine Group Inc.
North America was the largest region in the cell therapy market in 2025. The regions covered in the cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have introduced both challenges and opportunities for the cell therapy market by affecting the import and export of human cells, reagents, and specialized manufacturing equipment. Increased costs for critical raw materials and delays in supply chains have particularly impacted segments like stem cell therapy and CAR T-cell therapy, with North America and Europe experiencing the most disruption due to reliance on imported biologics. Some companies are leveraging tariffs to localize production and invest in domestic cell manufacturing facilities, potentially improving resilience and innovation in the long term.
The cell therapy market research report is one of a series of new reports that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell therapy involves the replacement or repair of damaged tissues and/or cells through the transplantation of human cells. Various types of cells can be employed in treatments for numerous diseases and disorders, supported by advanced technologies, innovative products, and creative approaches. In this therapy, patients receive live cells through injection, grafting, or implantation to achieve a therapeutic effect.
The primary techniques in cell therapy include stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell therapy, also called regenerative medicine, utilizes stem cells or their derivatives to trigger the healing of diseased, damaged, or injured tissues. Different therapy types include allogeneic and autologous therapies, which are applied in various fields such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and more.
The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $32.48 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to advancements in gene editing, automation in cell manufacturing, growing investment in cell therapy startups, increasing demand for regenerative medicine, expanding application across oncology and cvd. Major trends in the forecast period include personalized cell therapy development, allogeneic therapy advancements, improved cell storage & transportation, regulatory & compliance innovations, emerging clinical applications.
The rising prevalence of chronic diseases has supported the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), a chronic disease is a condition lasting one year or more that requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson’s disease. Stem cells offer potential benefits for patients with spinal cord injuries, type 1 diabetes, Parkinson’s disease, heart disease, cancer, and osteoarthritis. For example, in July 2024, the CDC reported significant updates on public health initiatives: over 944,800 Americans die annually from heart disease or stroke, representing more than one-third of all deaths; 1.7 million are diagnosed with cancer each year, with over 600,000 fatalities, making it the second leading cause of death; more than 38 million Americans have diabetes, with 98 million adults prediabetic; and obesity affects 20% of children and 42% of adults, increasing the risk of type 2 diabetes, heart disease, and certain cancers. This growing prevalence of chronic diseases has driven demand for cell therapies, contributing to market expansion.
Key players in the cell therapy market are developing next-generation, multi-targeted therapies backed by strong early-stage clinical data to improve treatment outcomes and address unmet needs in complex cancers. For instance, in June 2025, Johnson & Johnson, a US-based pharmaceutical company, reported promising initial results from its Phase 1b study of JNJ-4496, a dual-targeting CAR T-cell therapy designed to bind both CD19 and CD20 in relapsed or refractory large B-cell lymphoma. Early data presented at the 2025 EHA Congress showed 75-80% complete responses at the recommended Phase 2 dose, with no Grade 3-4 cytokine release syndrome. The therapy demonstrated encouraging safety, manageable neurotoxicity, and robust activity even in heavily pretreated patients, highlighting the potential of next-generation dual-targeting CAR T therapies and reinforcing Johnson & Johnson’s commitment to advancing innovative treatments for B-cell malignancies.
In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Sigilon Therapeutics for $34.6 million. This acquisition allows Lilly to strengthen its research and development in encapsulated cell therapies, specifically targeting Type 1 diabetes with its lead candidate, SIG-002, bolstering its position in the diabetes treatment market. Sigilon Therapeutics is a US-based biotechnology company focused on developing innovative cell therapies.
Major companies operating in the cell therapy market are Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics plc, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Athersys Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, Cellular Biomedicine Group Inc.
North America was the largest region in the cell therapy market in 2025. The regions covered in the cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have introduced both challenges and opportunities for the cell therapy market by affecting the import and export of human cells, reagents, and specialized manufacturing equipment. Increased costs for critical raw materials and delays in supply chains have particularly impacted segments like stem cell therapy and CAR T-cell therapy, with North America and Europe experiencing the most disruption due to reliance on imported biologics. Some companies are leveraging tariffs to localize production and invest in domestic cell manufacturing facilities, potentially improving resilience and innovation in the long term.
The cell therapy market research report is one of a series of new reports that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell therapy involves the replacement or repair of damaged tissues and/or cells through the transplantation of human cells. Various types of cells can be employed in treatments for numerous diseases and disorders, supported by advanced technologies, innovative products, and creative approaches. In this therapy, patients receive live cells through injection, grafting, or implantation to achieve a therapeutic effect.
The primary techniques in cell therapy include stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell therapy, also called regenerative medicine, utilizes stem cells or their derivatives to trigger the healing of diseased, damaged, or injured tissues. Different therapy types include allogeneic and autologous therapies, which are applied in various fields such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and more.
The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell Therapy Market Characteristics
3. Cell Therapy Market Supply Chain Analysis
4. Global Cell Therapy Market Trends and Strategies
5. Cell Therapy Market Analysis of End Use Industries
7. Global Cell Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell Therapy Total Addressable Market (TAM) Analysis for the Market
9. Cell Therapy Market Segmentation
10. Cell Therapy Market Regional and Country Analysis
11. Asia-Pacific Cell Therapy Market
12. China Cell Therapy Market
13. India Cell Therapy Market
14. Japan Cell Therapy Market
15. Australia Cell Therapy Market
16. Indonesia Cell Therapy Market
17. South Korea Cell Therapy Market
18. Taiwan Cell Therapy Market
19. South East Asia Cell Therapy Market
20. Western Europe Cell Therapy Market
21. UK Cell Therapy Market
22. Germany Cell Therapy Market
23. France Cell Therapy Market
24. Italy Cell Therapy Market
25. Spain Cell Therapy Market
26. Eastern Europe Cell Therapy Market
27. Russia Cell Therapy Market
28. North America Cell Therapy Market
29. USA Cell Therapy Market
30. Canada Cell Therapy Market
31. South America Cell Therapy Market
32. Brazil Cell Therapy Market
33. Middle East Cell Therapy Market
34. Africa Cell Therapy Market
36. Cell Therapy Market Competitive Landscape and Company Profiles
37. Cell Therapy Market Other Major and Innovative Companies
40. Cell Therapy Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Cell Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technique: Stem Cell Therapy; Cell Vaccine; Adoptive Cell Transfer (ACT); Fibroblast Cell Therapy; Chondrocyte Cell Therapy2) By Therapy Type: Allogeneic Therapies; Autologous Therapies
3) By Application: Oncology; Cardiovascular Disease (CVD); Orthopedic; Wound Healing; Other Applications
Subsegments:
1) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation; Mesenchymal Stem Cell Therapy; Embryonic Stem Cell Therapy; Induced Pluripotent Stem Cell Therapy2) By Cell Vaccine: Dendritic Cell Vaccine; Tumor-Infiltrating Lymphocyte (TIL) Vaccine; Antigen-Specific Cell Vaccine
3) By Adoptive Cell Transfer (ACT): CAR T-Cell Therapy; T-Cell Receptor (TCR) Therapy; Natural Killer (NK) Cell Therapy
4) By Fibroblast Cell Therapy: Dermal Fibroblast Therapy; Adipose-Derived Stem Cell Therapy
5) By Chondrocyte Cell Therapy: Autologous Chondrocyte Implantation (ACI); Chondral Graft Therapy
Companies Mentioned: Stempeutics Research Pvt. Ltd.; Osiris Therapeutics Inc.; Vericel Corporation; AlloSource; Anterogen Co. Ltd.; MediPost Co. Ltd.; Pharmicell Co. Ltd.; Corestem Inc.; Stemedica Cell Technologies Inc.; Adaptimmune Therapeutics plc; Mesoblast Ltd.; Cell Medica Ltd.; Cellerant Therapeutics Inc.; Kolon TissueGene Inc.; Athersys Inc.; Forticell Bioscience Inc.; Bone Therapeutics; Holostem Terapie Avanzate S.r.l; Fibrocell Science Inc.; AlloCure Inc.; TiGenix NV; Cells for Cells; Cellular Biomedicine Group Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell Therapy market report include:- Stempeutics Research Pvt. Ltd.
- Osiris Therapeutics Inc.
- Vericel Corporation
- AlloSource
- Anterogen Co. Ltd.
- MediPost Co. Ltd.
- Pharmicell Co. Ltd.
- Corestem Inc.
- Stemedica Cell Technologies Inc.
- Adaptimmune Therapeutics plc
- Mesoblast Ltd.
- Cell Medica Ltd.
- Cellerant Therapeutics Inc.
- Kolon TissueGene Inc.
- Athersys Inc.
- Forticell Bioscience Inc.
- Bone Therapeutics
- Holostem Terapie Avanzate S.r.l
- Fibrocell Science Inc.
- AlloCure Inc.
- TiGenix NV
- Cells for Cells
- Cellular Biomedicine Group Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 19.31 Billion |
| Forecasted Market Value ( USD | $ 32.48 Billion |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
